Short- or longer-term relugolix achieves sustained castration in patients with localized and advanced prostate cancer<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, March 29, 2024 (HealthDay News) — For patients with localized and advanced prostate cancer receiving radiotherapy, relugolix achieves sustained castration, according to a study published online March 7 in JAMA Oncology<\/em>.<\/p>\n Daniel E. Spratt, M.D., from the University Hospitals Seidman Cancer Center and Case Western Reserve University in Cleveland, and colleagues examined the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer in a multicenter, post-hoc analysis of patients with localized and advanced prostate cancer receiving radiotherapy in two randomized clinical trials. Data were included for 260 patients, 164 of whom received relugolix: 103 received radiotherapy and short-term ADT (patients received relugolix or degarelix for 24 weeks) and 157 received radiotherapy and longer-term ADT (patients received relugolix or leuprolide acetate injections during 48 weeks).<\/p>\n The researchers found that relugolix achieved castration rates (<50 ng\/dL) of 95 and 97 percent among patients receiving short- and longer-term ADT, respectively. At 12 weeks after short-term relugolix, 52 percent achieved testosterone levels to baseline or more than 280 ng\/dL. Among a subset of participants assessed for testosterone recovery, mean testosterone levels were 310.5 and 53.0 ng\/dL with relugolix and leuprolide acetate, respectively, at 90 days after longer-term ADT. There was no significant difference noted in castration resistance-free survival between the relugolix and leuprolide acetate cohorts. For short- or longer-term relugolix, adverse events of grade 3 or greater were uncommon.<\/p>\n “Relugolix appeared safe and effective at inducing rapid and sustained testosterone suppression across patients treated with short-term and longer-term ADT in combination with radiotherapy,” the authors write.<\/p>\n The C27003 study was sponsored by Millenium Pharmaceuticals, and the HERO study was sponsored by Sumitomo Pharma Switzerland. The manuscript was funded by Pfizer in collaboration with Sumitomo Pharma Switzerland.<\/p>\n